亚盛医药：截至2026年6月30日止六个月未经审核中期业绩公告

ASCENTAGE PHARMA GROUP INTERNATIONAL 6855 2026630 20266302025630 2026630302.244.52025630233.732.6(CER)202563068.511.929.3%20266302025630212.929.769.511.932.6%282.441.6 20266302025276.746.736.1%1,042.7153.72025630528.673.8168.929.032.0%2026630697.5102.888.614.264.3%2026630226.433.4®2026630817.0120.42025630590.882.5 20266301,895.6279.4(CER)202512312,470.1353.2574.573.823.3% Faiçal MiyaraJim Ziegler •202683FaiçalMiyaraChief Business OfficerCBOJim ZieglerChief Commercial OfficerCCO B •20265278.05(3)18A.0918A.112 0 2 661B BTKAPG-3288FDA(CDE)(IND) •20261BTKAPG-3288FDAIND20262APG-3288CDEIAPG-3288(PK) ®(CML)(ALL)®(CLL)(SLL)(AML)(HR-MDS)(Frost & Sullivan)20351,660 ®BCR-ABL1(TKI)T315ICMLBCR-ABL1 TKIT315I(CML)(-CP)(-AP)TKICML-CP®20251®CDEFDA(EMA)TKICMLIII(POLARIS-2)FDAEMA(Ph+)III(POLARIS-1)(SDH-)(GIST)III(POLARIS-3) Bcl-22025710BTKCLL/SLLCLL/SLLBcl-2Bcl-2III(1)BTKBTKCLL/SLL12GLORA(2)CLL/SLLGLORA-2(3)(AZA)AMLGLORA-3(4)AZAHR-MDSGLORA-4 Bcl-2Bcl-2/Bcl-xL(IAP)2p53(MDM2-p53)BCR-ABL1ALK FAK ROS2(PRC2)(PROTAC)Bcl-2IAPMDM2-p53 202663053725395 Dana-FarberMD 72026630 1.202111T315ITKI(CML-CP)(CML-AP)2022(NRDL)202331 2.202311TKI(CML-CP)2024(NRDL)202511 3.20257NMPABTK(CLL/SLL) 4.CLL/SLLAMLHR-MDS(MM)2 ® ®(TKI)®T315ICML-CPCML-APBCR-ABL1(TKI)CML-CPT315ITKI®20251® ®FDACML(ALL)(AML)GIST(ODD)(FTD)TKICML®EMA®2024(NCCN) CML2025®2025(CACA)2025(CSCO)2025 ® 1.202111T315ITKI(CML-CP)(CML-AP)2022(NRDL)202331 2.202311TKI(CML-CP)2024(NRDL)202511 ® •2026630®DTP879202563078212%®202563029534%2026630394 •TKIPh+ALLFDAEMAIII(POLARIS-1) •CML-CPT315IFDAEMAIII(POLARIS-2)•(SDH)(GIST)III(POLARIS-3)•Bcl-2 •2026611614CMLPh+ ALL31(EHA2026) IbASXL1CML-CPTKIASXL122CML-CP40.9%(9/22)ASXL144.4%(4/9)ASXL122.2%(2/9)(MMR)1MR4.5 105≥2TKI≥18MMRCML-CP1:2TKI6M M R54.3%vs 10.0%P<0.00112MMR57.14%21.43%(P<0.0001)3-4(42.86%)(17.14%)3-478.57%TKIAE≥2TKICML-CP POLARIS-11Ph+ALLIII(MRD)(CR)63.0% Ib(R/R) Ph+ ALL1740%ABL1T315I9(ORRCR+CRCRi88.9%MRD66.7%8/1222893.3%14/15228MMR(CSF)ABL1 •2026529622026(ASCO) TIbR / R( C M L - L B P )B( P h +BCP-ALL)91%(10/11)C RC R i67% (8/12)P C RB C R : : A B L1(≤0.01%)80%(8/10)MRD(≤0.01%)(AE)1-2 47CML-CPCML-CPTKIT315I20261144276.2%(32/42)(CCyR)47.6%(20/42)MMR24CCyR91.3%MMR60.9%TKICML-CPCCyR81.3%MMR50.0% SDHp38-MAPK-CD36SDH26SDHGIST6(23.1%)(PR)(PFS)25.76SDH4(SD)≥466.7%PFS8.25 •20264174222026(AACR)(EC)(MCL)BTK •2026352(EBMT2026)(BC-CML)69TKIBC-CML43TKI1/2TKI26TKI(MMR)(CMR)53.8%23.1%TKI16.3%4.7%1(OS)89%1(PFS)78%TKI70.8%68%(NRM)10.6%TKI23%BC-CML ® •2026POLARIS-1POLARIS-2POLARIS-3 ® ®Bcl-2Bcl-220257®BTK(CLL/SLL)®Bcl-2Bcl-2®2026CSCOCLL/SLL2026CSCOAML®CLL/SLL(NHL)AML MM MDSFDA®(FL)WMCLLMM AML ® 1.20257BTKCLL/SLL ® •2026630®DTP41560 •AZAHR-MDSIII(GLORA-4)GLORA-4FDAEMA•AZAAMLIII(GLORA-3)•BTKCLL/SLLIII(GLORA-2)•BTKBTKCLL/SLLIII(GLORA)GLORAFDAEMA•(MM)Ib/II•AML/MDSIb/II•AML/MDSIb/II •2026611614CLL/SLL31(EHA2026) 30AML25CR/CRi72%MDS32CRi≥3(TEAE)27%23%20% AZAMDS10HR-MDS55(ORR)70%60%80%1.84AZA1AZA(CR)MDS IINCT05147467R/R CLL/SLL77BTKiR/R CLL/SLL72PFS23.9IRCORR62.5%TP53del(17p)SF3B1KIT BLM SETD2PFSBTKiR/R CLL/SLL •202512Med1b/2(NCT04215809)CLL/SLL176346399130.1%del(17p)TP532ORR67.4%29/43R/RORR84.6%33/39R/R22ORR100%65R/R CLL/SLLORR96.9%57CLL/SLL ••2026GLORAGLORA-2 GLORA-3GLORA-4•2026 APG-2449 APG-2449(FAK)(ALK)C-ROS1(ROS1)(TKI)CDEFAKCSF PKAPG-2449APG-2449ALK TKI(NSCLC)APG-2449ALK TKINSCLCFAK(pFAK)APG-2449PFSpFAKALK TKIMAPKRASMEKBRAF APG-2449 •(CDE)IIIAPG-2449(ALK) TKI(NSCLC)ALKNSCLC •APG-2449Ib/II •20264174222026(AACR 2026)APG-2449BRAF V600EAPG-2449FAKMAPK 18A.05APG-2449 Alrizomadlin (APG-115) Alrizomadlin(APG-115)MDM2-p53MDM2p53p53Alrizomadlin AlrizomadlinFDA(ODD)A M LI I B - I ValrizomadlinFDA(RPDD)alrizomadlinCDE(NB)(RMS)(EWS) alrizomadlin alrizomadlin •alrizomadlinPD-1Ib/II•alrizomadlinT(R/R T-PLL)(NHL)IIa CDEalrizomadlin •alrizomadlinPD-1JS001(LPS)Ib/II•alrizomadlinAMLMDSIb•alrizomadlinIalrizomadlinRMS(STS) •2026530alrizomadlin2026ASCOalrizomadlin1(CR)alrizomadlin17(ORR)23.5%121(PR)(DCR)70.6% •20263alrizomadlinTP53I(NCT03781986)NatureCommunicationsalrizomadlinTP53(ACC)(ORR)15%(PFS)10.5AlrizomadlinMDM2-p53 18A .05A L R I Z O M A D L I N(APG-115) Pelcitoclax (APG-1252) PelcitoclaxBcl-2Bcl-xL(SCLC)(NSCLC)(NHL)APG-1252FDA(ODD)SCLC PelcitoclaxPelcitoclax Pelcitoclax Pelcitoclax •pelcitoclax(EGFR)NSCLCIb•pelcitoclax(R/R NHL)Ib/II •pelcitoclaxMEKcobimetinibI•pelcitoclaxAZAAMLIb/II •2 0 2 67(J o u r n a l f o r I m m u n o T h e r a p yo fC a n c e r ,J I T C )I b( N C T 0 4 0 0 1 7 7 7 )pelcitoclax(APG-1252)EGFR TKIEGFRNSCLC(PK)TKITKIBcl-xLTP53Bcl-2/Bcl-xLEGFR-TKIEGFRNSCLC Pelcitoclax •IPelcitoclaxR/R AMLPK • 1 8 A . 0 5P E L C I T O C L A X(APG-1252) APG-5918 APG-5918(EED)EEDPRC2PRC2APG-5918(CKD) (FDA)IAPG-5918 APG-5918 •APG-5918I•APG-5918I(SAD)(MAD) •20264174222026AACRAPG-5918APG-5918(SCLC)I APG-5918 •2026APG-5918 18A.05APG-5918 APG-3288 A P G - 3 2 8 8( P R O T A C )B T KBTK-PROTAC-Cereblon E3BTKBTKAPG-3288BTKBTKC481SBCR-BTKBTKBTKBTKAPG-3288BTKPK APG-3288 •APG-32882